S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
Log in
(Ad)
Its partners include AT&T, Verizon, Sprint and T-Mobile. It owns more than 200 patents. And analysts say it has "home-run potential." Yet this 5G superstock trades for only $5 a share.

NYSE:AMRX - Amneal Pharmaceuticals Stock Price, Forecast & News

$5.32
+0.22 (+4.31 %)
(As of 01/21/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.09
Now: $5.32▼
$5.38
50-Day Range
$3.47
MA: $4.61▼
$5.55
52-Week Range
$2.27
Now: $5.32▼
$14.79
Volume1.62 million shs
Average Volume1.84 million shs
Market Capitalization$1.59 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.61
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. Read More…

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:AMRX
Previous Symbol
CUSIPN/A
CIK1723128
Webhttp://www.amneal.com/
Phone908-947-3120

Debt

Debt-to-Equity Ratio6.91
Current Ratio2.25
Quick Ratio1.50

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio20.46
P/E Growth0.71

Sales & Book Value

Annual Sales$1.86 billion
Price / Sales0.85
Cash Flow$1.49 per share
Price / Cash Flow3.57
Book Value$3.00 per share
Price / Book1.77

Profitability

EPS (Most Recent Fiscal Year)$0.95
Net Income$-169,730,000.00
Net Margins-19.61%
Return on Equity23.17%
Return on Assets3.94%

Miscellaneous

Employees6,000
Outstanding Shares299,099,000
Market Cap$1.59 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive AMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.

AMRX Rates by TradingView

(Ad)

A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

Amneal Pharmaceuticals (NYSE:AMRX) Frequently Asked Questions

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals Inc (NYSE:AMRX) issued its quarterly earnings results on Wednesday, November, 6th. The company reported $0.04 earnings per share for the quarter, missing analysts' consensus estimates of $0.13 by $0.09. The company earned $378.30 million during the quarter, compared to the consensus estimate of $403.90 million. Amneal Pharmaceuticals had a negative net margin of 19.61% and a positive return on equity of 23.17%. Amneal Pharmaceuticals's revenue for the quarter was down 20.6% on a year-over-year basis. During the same period last year, the company earned $0.28 earnings per share. View Amneal Pharmaceuticals' Earnings History.

When is Amneal Pharmaceuticals' next earnings date?

Amneal Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Amneal Pharmaceuticals.

What price target have analysts set for AMRX?

12 brokers have issued 1-year target prices for Amneal Pharmaceuticals' shares. Their forecasts range from $2.50 to $14.00. On average, they expect Amneal Pharmaceuticals' share price to reach $6.30 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price. View Analyst Price Targets for Amneal Pharmaceuticals.

What is the consensus analysts' recommendation for Amneal Pharmaceuticals?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 2 sell ratings, 6 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amneal Pharmaceuticals.

What are Wall Street analysts saying about Amneal Pharmaceuticals stock?

Here are some recent quotes from research analysts about Amneal Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. The company operates primarily in North America, Asia and Europe. Amneal Pharmaceuticals LLC, formerly known as Impax Laboratories Inc., is based in New Jersey, United States. " (1/7/2020)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our OW rating and 12-month PT of $35 for AMRX shares post a 4Q18 beat and despite lower than anticipated guidance for 2019. We still believe that AMRX will be able to successfully grow from a mid-size generics company into a leading generics and specialty pharma company. Therefore, upward earnings revisions in 2020+ should drive the stock higher. These upward earnings revisions should come from: 1) new generic drug launches, 2) operating margin expansion, 3) high-margin brand drug sales, and 4) strategic M&A as well as tuck-in deals." (2/28/2019)

Has Amneal Pharmaceuticals been receiving favorable news coverage?

Media stories about AMRX stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Amneal Pharmaceuticals earned a news impact score of 2.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Amneal Pharmaceuticals.

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 4,960,000 shares, a decline of 13.9% from the December 15th total of 5,760,000 shares. Based on an average daily volume of 2,900,000 shares, the days-to-cover ratio is currently 1.7 days. Approximately 6.0% of the company's stock are sold short. View Amneal Pharmaceuticals' Current Options Chain.

Who are some of Amneal Pharmaceuticals' key competitors?

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Exelixis (EXEL), Nektar Therapeutics (NKTR), Canopy Growth (CGC), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Opko Health (OPK) and Progenics Pharmaceuticals (PGNX).

Who are Amneal Pharmaceuticals' key executives?

Amneal Pharmaceuticals' management team includes the folowing people:
  • Mr. Paul M. Bisaro, Exec. Chairman (Age 58)
  • Mr. Chirag K. Patel, Co-Founder & Co-Chairman (Age 52)
  • Mr. Chintu Patel, Co-Founder & Co-Chairman (Age 47)
  • Mr. Robert A. Stewart, Pres, CEO & Director (Age 51)
  • Ms. Nikita Shah, Sr. VP & Chief HR Officer (Age 41)

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FNY Investment Advisers LLC (0.02%), Assenagon Asset Management S.A. (0.01%) and NEXT Financial Group Inc (0.00%). Company insiders that own Amneal Pharmaceuticals stock include Andrew S Boyer, Bryan M Reasons, International Ltd Fosun, Joseph Todisco, Nikita Shah, Paul Bisaro, Peter R Terreri, Pradeep Bhadauria and Ted C Nark. View Institutional Ownership Trends for Amneal Pharmaceuticals.

Which major investors are selling Amneal Pharmaceuticals stock?

AMRX stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. View Insider Buying and Selling for Amneal Pharmaceuticals.

Which major investors are buying Amneal Pharmaceuticals stock?

AMRX stock was bought by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC and NEXT Financial Group Inc. Company insiders that have bought Amneal Pharmaceuticals stock in the last two years include Andrew S Boyer, International Ltd Fosun, Joseph Todisco, Paul Bisaro, Pradeep Bhadauria and Ted C Nark. View Insider Buying and Selling for Amneal Pharmaceuticals.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $5.32.

How big of a company is Amneal Pharmaceuticals?

Amneal Pharmaceuticals has a market capitalization of $1.59 billion and generates $1.86 billion in revenue each year. The company earns $-169,730,000.00 in net income (profit) each year or $0.95 on an earnings per share basis. Amneal Pharmaceuticals employs 6,000 workers across the globe.View Additional Information About Amneal Pharmaceuticals.

What is Amneal Pharmaceuticals' official website?

The official website for Amneal Pharmaceuticals is http://www.amneal.com/.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-947-3120 or via email at [email protected]


MarketBeat Community Rating for Amneal Pharmaceuticals (NYSE AMRX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  298 (Vote Outperform)
Underperform Votes:  363 (Vote Underperform)
Total Votes:  661
MarketBeat's community ratings are surveys of what our community members think about Amneal Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Featured Article: Why is the ex-dividend date different from the record date?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel